文献速递类风湿关节炎

JAK抑制剂处方演变:监管警告对类风湿关节炎注册研究的影响

Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings.
PubMed 文献 · Semin Arthritis Rheum · 2026-02-12

该研究基于12国注册库中40,019例成人RA患者的55,365个治疗疗程,分析2015至2024年JAKi处方趋势与8项监管事件的关系。JAKi使用从2015年<1%升至2024年>20%,FDA和EMA警告后启动趋势放缓、停药增加,托法替布受影响最大。

要点

  • JAKi使用从2015年<1%升至2024年>20%,2019年FDA和2022年EMA警告后增速放缓。
  • 托法替布启动下降、停药增加最显著;巴瑞替尼受安全信号影响较小,非戈替尼使用稳步增加。
  • 高危人群(≥65岁伴心血管危险因素)在2019年EMA警告后JAKi停药率显著上升。

核心结论

  • 监管安全通讯显著影响真实世界中JAKi的处方模式。
  • 托法替布受影响最大,表现为启动减少和停药增加。

研究设计与样本

  • 观察性研究,分析12国注册库2015至2024年40,019例成人RA患者的55,365个治疗疗程(12,559个JAKi和42,806个其他bDMARDs)。
  • 采用分段回归模型分析8项主要监管事件前后的趋势,并使用校正人口学、疾病和治疗变量的逻辑广义估计方程(GEE)。

主要发现

  • JAKi使用从2015年<1%升至2024年>20%,2019年FDA和2022年EMA警告后增速放缓。
  • 首次FDA警告及2021年初MACE和癌症风险增加发表后,启动趋势显著放缓,主要影响托法替布。
  • 2022年EMA警告后停药激增,主要影响托法替布;ORAL Surveillance试验发表后乌帕替尼启动下降、停药增加。
  • 巴瑞替尼使用受安全信号影响较小,非戈替尼使用稳步增加。
  • 高危人群(≥65岁伴心血管危险因素)在2019年EMA警告后JAKi停药率显著上升。

临床怎么用

  • 临床处方JAKi时应考虑监管安全警告对药物选择的影响,托法替布使用需更谨慎评估风险获益。
  • 对≥65岁伴心血管危险因素的高危RA患者,应加强JAKi治疗期间的监测和再评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Janus kinase inhibitors (JAKi) are effective for treating rheumatoid arthritis (RA), but post-marketing safety concerns have triggered regulatory warnings and updated guidelines. The impact of these communications on real-world prescribing remains unclear. OBJECTIVES: To assess the impact of major regulatory safety warnings on the initiation, discontinuation, and switching patterns of JAKi in RA patients, using data from 12 national registries. METHODS: This observational study analyzed 55,365 treatment courses (12559 JAKi and 42806 other bDMARDs) from 40,019 adult RA patients between 2015 and 2024. Segmented regression models examined trends around eight major regulatory events. Logistic generalized estimating equations (GEE), adjusted for demographic, disease, and treatment variables, were used. Sensitivity and subgroup analyses, including at-risk populations (age ≥65 with cardiovascular risk factors), were conducted. RESULTS: JAKi use rose from <1 % in 2015 to >20 % by 2024, with slowdowns after the 2019 FDA and 2022 EMA warnings. Initiation trends significantly slowed after the first FDA warning and the publication of increased risks for MACE and cancer in early 2021, primarily affecting tofacitinib. Discontinuations surged following the EMA's 2022 warning, again mainly affecting tofacitinib. Upadacitinib initiations also declined, and discontinuations increased after the publication of the ORAL Surveillance trial. Baricitinib use appeared to be less impacted by the safety signals, while filgotinib use steadily increased. Among the at-risk population, the rate of JAKi discontinuation significantly rose after the 2019 EMA warning. CONCLUSIONS: Regulatory safety communications significantly influenced real-world JAKi prescribing patterns. Tofacitinib was most affected through both declines in initiation and increases in discontinuation.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Mongin D, Aymon R, Choquette D, et al. Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings. Semin Arthritis Rheum. 2026. PMID: 41722160. doi:10.1016/j.semarthrit.2026.152946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。